MX2020010651A - Regímenes de dosificación para el tratamiento de trastornos proliferativos. - Google Patents

Regímenes de dosificación para el tratamiento de trastornos proliferativos.

Info

Publication number
MX2020010651A
MX2020010651A MX2020010651A MX2020010651A MX2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A MX 2020010651 A MX2020010651 A MX 2020010651A
Authority
MX
Mexico
Prior art keywords
treatment
proliferative disorders
dosage regimens
curcuminoids
effective amount
Prior art date
Application number
MX2020010651A
Other languages
English (en)
Spanish (es)
Inventor
Peter Sordillo
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2020010651A publication Critical patent/MX2020010651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020010651A 2018-04-09 2019-03-28 Regímenes de dosificación para el tratamiento de trastornos proliferativos. MX2020010651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
PCT/US2019/024495 WO2019199469A1 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
MX2020010651A true MX2020010651A (es) 2021-01-15

Family

ID=68164516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010651A MX2020010651A (es) 2018-04-09 2019-03-28 Regímenes de dosificación para el tratamiento de trastornos proliferativos.

Country Status (11)

Country Link
US (2) US11813356B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773529B1 (cg-RX-API-DMAC7.html)
JP (2) JP7241426B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240027843A (cg-RX-API-DMAC7.html)
CN (1) CN112272555A (cg-RX-API-DMAC7.html)
AU (1) AU2019250832B2 (cg-RX-API-DMAC7.html)
CA (1) CA3096591C (cg-RX-API-DMAC7.html)
ES (1) ES3061642T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020010651A (cg-RX-API-DMAC7.html)
TW (1) TWI737974B (cg-RX-API-DMAC7.html)
WO (1) WO2019199469A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A4 (en) 2023-02-28 2026-06-17 Panasonic Ip Man Co Ltd SECONDARY BATTERY WITH NON-AQUEAL ELECTROLYTE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
UA99914C2 (ru) 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
CN101766619B (zh) * 2008-12-30 2011-08-24 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
EP2501372A4 (en) 2009-11-19 2013-04-10 Signpath Pharma Inc INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER
HK1208907A1 (en) 2012-06-14 2016-03-18 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
WO2014036534A1 (en) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
WO2015077640A1 (en) 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
JP6895252B2 (ja) * 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ikrチャネルの薬剤誘発性阻害のリポソームによる軽減
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Also Published As

Publication number Publication date
EP3773529C0 (en) 2025-12-24
KR102637598B1 (ko) 2024-02-16
KR20200141062A (ko) 2020-12-17
EP3773529A1 (en) 2021-02-17
AU2019250832B2 (en) 2022-10-27
CA3096591A1 (en) 2019-10-17
ES3061642T3 (en) 2026-04-06
US20210161815A1 (en) 2021-06-03
US11813356B2 (en) 2023-11-14
EP3773529A4 (en) 2021-12-22
TW201946613A (zh) 2019-12-16
JP2023030106A (ja) 2023-03-07
US20240050372A1 (en) 2024-02-15
AU2019250832A1 (en) 2020-10-29
CA3096591C (en) 2023-06-27
EP3773529B1 (en) 2025-12-24
US12551436B2 (en) 2026-02-17
KR20240027843A (ko) 2024-03-04
CN112272555A (zh) 2021-01-26
WO2019199469A1 (en) 2019-10-17
JP7241426B2 (ja) 2023-03-17
JP2021521130A (ja) 2021-08-26
TWI737974B (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
MY201127A (en) Use of a vegf antagonist to treat angiogenic eye disorders
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
IN2015DN00376A (cg-RX-API-DMAC7.html)
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
CY1125384T1 (el) Συνθεση και φαρμακευτικα προϊοντα για μειωση τοπικου λιπους και σωματικου βαρους και η χρηση αυτων
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
UY38948A (es) Régimen de dosificación para agentes anti-dll3
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
PT3762015T (pt) Guselkumab para utilização no tratamento da doença de crohn com um regime de dosagem
PH12020551726A1 (en) Treatment of atopic dermatitis
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.